CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
Are big 4 ASX bank shares ‘risky’? Let’s take a look at how shares like Commonwealth Bank (ASX:CBA) and Westpac Banking Corp (ASX:WBC) stack up compared to the market.
Top performing fund manager, Hyperion Asset Management, recently released an update on their Hyperion Australian Growth Companies Fund.
CSL Limited (ASX:CSL) has revealed that it will manufacture and supply COVID-19 vaccines to Australia.
In the second installment of our ASX Reporting Season Results Recap, myself and Wattle Partners financial adviser Drew Meredith, look at the reports from EML Payments Ltd (ASX:EML), Kogan.com Ltd (ASX:KGN), Pro Medicus Ltd (ASX:PME) and JB Hi-Fi Limited (ASX:JBH).
The S&P/ASX 200 (INDEXASX: XJO) is set to take a backwards step at the open. It was a busy day yesterday as a number of companies released their annual results. Here’s what you missed.
CSL Limited (ASX: CSL) shares solidified their position of one of Australia’s true global leaders.
CSL Limited (ASX:CSL) has reported its FY20 report to investors, is the CSL share price a buy?
ASX blue chips have attracted investors for decades. But are they even worth investing in these days?
The S&P/ASX 200 (INDEXASX: XJO) is set to open flat on Tuesday. Qantas Airways Limited (ASX: QAN) and Kogan.com Ltd (ASX: KGN) are in the news.
